European Commission Research & Innovation Initiatives and Programme Opportunities

European Innovation Council (EIC) Transition

Snapshot overview

The European Innovation Council (EIC) supports innovations with breakthrough and market creating potential. It provides funding through open calls with no defined thematic priorities or a challenge-driven approach, focusing on a specific thematic breakthrough. EIC is divided into three different schemes: EIC Pathfinder, EIC Transition, and EIC Accelerator. EIC Transition supports the maturation and validation of novel technology in the lab and in relevant application environments, as well as the development of a business case and business model to commercialise this novel technology.

Under the 2024 work programme, one call for proposals is forthcoming: EIC Transition Open, for projects in any field of science, technology or application without predefined thematic priorities.


European Innovation Council (EIC) Transition

Institution/ DG/ Agency responsible at EU-level

European Innovation Council

Work programme

EIC is a programme under Horizon Europe covering 2021-2027.

Programme budget

The total indicative budget for 2024 is EUR 94 million.

Project budget

Up to EUR 2.5 million

Type of funding

Grant, no contribution required. EIC Awardees will also be provided with access to a range of externally contracted, bespoke EIC Business Acceleration Services (BAS) at any stage of development of their activities.

Target participants

Single applicants (SMEs, spin-offs, start-ups, research organisations, universities) or small consortia (minimum 2, maximum 5 eligible entities).

Programme scope

EIC Transition funds innovation activities that go beyond the experimental proof of principle in laboratory to support the maturation and validation of novel technology in the lab and in relevant application environments and the development of a business case and (business) model towards the innovation’s future commercialisation.

Participant criteria

Applicants based in the following geographical areas are eligible for funding:

  • European Union Member States
  • Countries associated to Horizon Europe
  • Low- and middle-income countries (LMICs)

The following types of application are accepted:

  • Single applicants (SMEs, spin-offs, start-ups, research organisations, universities)
  • Small consortia (minimum 2, maximum 5 eligible entities)

EIC Transition is restricted to proposals based on results generated by the following eligible projects:

  • EIC Pathfinder projects (including projects funded under the Horizon 2020 EIC pilot Pathfinder, FET-Open, FET-Proactive, CSA and CSA Lump sum FET Innovation Launchpad and FET Flagships calls)
  • European Research Council Proof of Concept projects funded Horizon 2020 or Horizon Europe
  • Research and Innovation Actions directly funded under Horizon 2020 Societal challenges and Leadership in Industrial Technologies and under Horizon Europe pillar II, with an eligible TRL39
  • European Defence Fund (EDF), including the Preparatory Action on Defence Research, research projects, but only for proposals which are focused on civil applications (including dual use)
Project duration

Depending on the specific project

Average time from submission to project kick-off

The proposal will be evaluated first by EIC expert evaluators. Applicants will be informed about the result of this evaluation, including feedback on their proposal, indicatively within nine weeks after the cut-off. If the proposal successfully passes this first evaluation phase, applicants will be invited for a face-to-face interview, which will be organised approximately 13 weeks after the cut-off.

If the proposal is successful, applicants can expect their grant agreement to be signed within six months from the call deadline (indicative) and are expected to start their project within two months after signing the grant agreement.

R&D stage

Research and development beyond the experimental proof of principle in laboratory

Intellectual property

EIC Transition projects are subject to provisions to ensure open access to scientific publications and to promote the uptake of research results.

Project database

EIC Transition Open: Overview here, Call for proposals not published yet

  • EIC Transition Open: Forthcoming
      • Submission deadline 18 September 2024
Contact details & more information

What type of funding are you looking for?

  • Grant:
    Grants are direct financial contributions from the European Union budget awarded by way of a donation to third-party beneficiaries (usually non-profit-making organisations) engaged in activities that serve EU policies.
  • Loan:
    Loans are measures of financial support provided on a complementary basis from the budget in order to address specific policy objectives of the European Union. Such instruments are implemented in partnership with public and private institutions such as banks, venture capitalists or angel investors.

What stage of development are you seeking R&I funding for?

  • Basic science: Basic science covers the various exploratory steps even prior to discovery
  • Discovery: Drug discovery aims to find potential disease-altering targets, such as a gene or a protein in humans. Prior to testing candidate compounds for safety
  • Preclinical development: Preclinical development concerns the testing of candidate compounds for safety in specific indications or disease conditions. Introduction of candidate compound in living biological systems (animals)
  • Phase 1 clinical trials: These are the first clinical trials on humans(usually 20-80 volunteers) testing the safety, side effects, best dose, and timing of a new treatment
  • Phase 21/2b clinical trials: This is the follow-up trial with roughly 100 to 500 patients to analyse efficacy and safety
  • Phase 3 clinical trials: These trials usually involve several hundreds to many thousands patients and tests the results of earlier clinical trials on larger populations to generate robust data on safety, efficacy and benefit-risk relationships of the medicine. Comparison to placebo and/or active comparator (best standard treatment)
  • Registration & launch: This concerns post-study, prior to launch, activities related to market launch. That can include, among others, marketing authorisation, regulatory activities, post-study communication or HTA
  • Introduction & delivery: This concerns all post-launch activities

What do you want to develop?

  • Treatment or vaccine:
    Refers to a drug or vaccine
  • Diagnostic or medical device:
    Refers to diagnostics and medical devices
  • Platform:
    Refers to a digital health platform or medical app
  • Knowledge:
    Refers to conducting research to help build our understanding on a topic
  • Standards:
    Refers to creating a benchmark for a specific issue

What type of organisation are you?

  • Small & medium-sized enterprises:
    <250 employees, annual revenue <EUR 50,000,000) or balance sheet < EUR43 million. This applies to individual firms only. If part of larger group, check the User Guide:
  • Large enterprises:
    >250 employees or annual revenue > EUR 50,000,000. Non-profit organisation (non-governmental organisations that are recognised with a non-profit status)
  • Non-profit organisations:
    Non-governmental organisations that are recognised with a non-profit status
  • Academic:
    Linked to a university or equivalent
  • Public:
    Local, regional, federal government representative

What stage of diagnostics development does your research aim to cover?

  • Development:
    Product development
  • Validation:
    Lab and clinical validation
  • Evaluation & Authorisation:
    Regulatory approvals
  • Access:

What stage of medicine or vaccine development does your research aim to cover?

  • Discovery and development:
    Identification of promising compounds for development and initial experiments to gather information
  • Preclinical research:
    Laboratory and animal testing to answer basic questions about safety
  • Phase 0 (clinical):
    Testing on limited number of subjects at subtherapeutic doses
  • Phase I (clinical):
    Testing on <100 healthy subjects with the disease/condition
  • Phase II (clinical):
    Testing on up to several hundred subjects with the disease/condition
  • Phase III (clinical):
    Testing on 300 to 3,000 volunteers with the disease/condition
  • Preregistration / Phase IV (clinical):
    Testing on several thousand volunteers with the disease/condition
  • Clinical (unspecified):
    Clinical phase unknown
  • Evaluation & Authorisation:
    Activities relating to marketing authorisation
  • Access:

Where are you based?

  • Africa : Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic (CAR), Chad, Comoros, Congo (Democratic Republic of the), Congo (Republic of the), Cote d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe
  • America (non-US & Canada) : Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela
  • Asia-Pacific : Afghanistan, Australia, Bangladesh, Bhutan, Burma, Brunei, Cambodia, China (including special administrative regions of Hong Kong and Macau), Cook Islands, Federated States of Micronesia, Fiji, India, Indonesia, Japan, Kiribati, Laos, Malaysia, Maldives, Marshall Islands, Mongolia, Nepal, New Caledonia, New Zealand, Niue, North Korea, Pakistan, Palau, Papua New Guinea, Philippines, Singapore, Solomon Islands, South Korea, Sri Lanka, Taiwan, Thailand, Timor-Leste, Tonga, Tuvalu, Vanuatu, Vietnam
  • Europe (non-EU) : Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Iceland, Kosovo, Liechtenstein, Moldova, Monaco, Montenegro, North Macedonia, Norway, Russia, San Marino, Serbia, Switzerland, Turkey, Ukraine, United Kingdom
  • European Union (EU) : Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden
  • Middle East : Cyprus, Lebanon, Syria, Iraq, Iran, Israel, Jordan, Saudi Arabia, Kuwait, Qatar, Bahrain, United Arab Emirates, Oman, Yemen
  • United States (US) & Canada : United States, Canada

What type of organisation are you?

  • Small and medium-sized enterprise (SME):
    Staff headcount 50 < and turnover ≤ EUR 10 m or balance sheet total ≤ EUR 10 m (small); Staff headcount 250 < and turnover ≤ EUR 50 m or balance sheet total ≤ EUR 43 m (medium)
  • Large enterprise:
    Staff headcount > 250
  • Non-profit organisation:
    Association, foundation, or equivalent
  • Academic:
    University, research institute, or equivalent
  • Individual:
    Private citizen
  • Public sector:
    Local, regional, federal government representative
  • Other:
    None of the above or uncertain